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ABSTRACT
3-Phosphoglycerate dehydrogenase (PHGDH) has recently been identified 
as an attractive target in cancer therapy as it links upregulated glycolytic flux to 
increased biomass production in cancer cells. PHGDH catalyses the first step in the 
serine synthesis pathway and thus diverts glycolytic flux into serine synthesis. We 
have used siRNA-mediated suppression of PHGDH expression to show that PHGDH is 
a potential therapeutic target in PHGDH-amplified breast cancer. Knockdown caused 
reduced proliferation in the PHGDH-amplified cell line MDA-MB-468, whereas breast 
cancer cells with low PHGDH expression or with elevated PHGDH expression in the 
absence of genomic amplification were not affected. As a first step towards design of 
a chemical probe for PHGDH, we report a fragment-based drug discovery approach 
for the identification of PHGDH inhibitors. We designed a truncated PHGDH construct 
that gave crystals which diffracted to high resolution, and could be used for fragment 
soaking. 15 fragments stabilising PHGDH were identified using a thermal shift assay 
and validated by X-ray crystallography and ITC competition experiments to exhibit 
1.5-26.2 mM affinity for PHGDH. A structure-guided fragment growing approach was 
applied to the PHGDH binders from the initial screen, yielding greater understanding 
of the binding site and suggesting routes to achieve higher affinity NAD-competitive 
inhibitors.
INTRODUCTION
Deregulated metabolism in cancer provides a 
variety of potential targets for drug discovery that 
have yet to be explored. Many tumour types have been 
shown to preferentially metabolise glucose to lactate, 
irrespective of oxygen levels, a phenomenon termed 
the Warburg effect. This aerobic glycolysis process is 
less efficient in the production of ATP than is oxidative 
phosphorylation, but provides cancer cells with the 
means of balancing energy and biomass production [1]. 
Human 3-phosphoglycerate dehydrogenase (PHGDH) 
is responsible for the NAD+-dependent conversion of 
3-phosphoglycerate (3-PG) to phosphohydroxypyruvate 
(PHP), which is the first step in the de novo serine 
synthesis pathway. Thus, PHGDH activity diverts 
glycolytic flux into biomass production. Early research 
showing increased PHGDH activity in rat hepatomas 
and colon carcinoma compared to matched healthy tissue 
pointed towards the importance of PHGDH activity in 
cancer [2, 3]. More recent findings have extended these 
observations to reveal that PHGDH, the gene encoding 
PHGDH, is frequently amplified in melanoma and 
certain forms of breast cancer [4, 5]. A previous study 
had already shown a correlation between high PHGDH-
mRNA levels and poor five-year survival in ER-negative 
basal breast cancers [6]. Consistent with the genetic 
data, knockdown of PHGDH in melanoma and breast 
cancer cell lines containing a PHGDH amplification, 
resulted in decreased cell viability [4, 5]. In addition, 
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PHGDH suppression inhibited the growth of mammary 
tumours in mice, although the suppressive effect seemed 
to depend on the tumour stage, as a similar in vivo 
study in more established mammary tumours reported 
no significant reduction in tumour growth following 
PHGDH knockdown [4, 7]. Another study revealed 
high PHGDH expression in cervical adenocarcinoma 
samples, and knockdown of PHGDH in a related 
xenograft model significantly inhibited cell proliferation 
and halted tumour progression in vivo [8]. Interestingly, 
overexpression of PHGDH in a non-tumourigenic cell 
line drove phenotypic alterations typical of malignant 
transformation [4]. Analysis of PHGDH levels in 
different cancer cell lines revealed upregulation of 
PHGDH mRNA rather than changes in enzymatic 
activity to be the reason for elevated PHGDH activity in 
human tumour cells [9]. Raised PHGDH mRNA levels 
have been reported in the colon adenocarcinoma cell 
line COLO320DM and in the murine lymphoma cell 
line BW5147.G.1.4 [9]. Subsequent studies showed 
significantly enhanced PHGDH expression in melanoma 
and breast cancer, indicating that these cancer types 
might be susceptible to treatment by PHGDH inhibition 
[4-6]. In addition, PHGDH expression was found to 
correlate with tumour grade in glioma cells and tumour 
stage in cervical cancer [10, 11].
The initial target validation, performed in in vitro 
and in vivo knockdown models, points towards PHGDH 
as a promising target in cancer. However, to date only 
two studies have reported small molecule inhibitors of 
PHGDH [12, 13]. The two reported lead compounds CBR-
5884 (IC50 = 33 ± 12 μM) [13] and NCT-503 (IC50 = 
2.5 ± 0.6 μM) [12] (Figure 3c) have similar potency in in 
vitro biochemical assays. Both compounds were shown to 
inhibit PHGDH activity in a non-competitive manner and 
to selectively target cancer cell lines dependent on de novo 
serine synthesis [12, 13].
In an effort to further build on the reported target 
validation and to provide a chemical probe to interrogate 
the role of PHGDH activity in cancer, we explored the 
effects of PHGDH knockdown in a panel of cancer cell 
lines, and developed assays and a crystal system for 
the identification of fragments that bind to the cofactor 
binding-site of PHGDH.
RESULTS
PHGDH expression in different cancer types
In order to extend the reported analyses into 
other cancer types, we analysed PHGDH protein 
levels by Western blot in a panel of 50 different 
cell lines belonging to ten different cancer types 
(Figure 1, Supplementary Figure S1). The observed 
PHGDH expression levels varied from almost no 
expression to 6-fold higher expression compared to 
K562 cells. Of the cell lines investigated, those derived 
from breast cancer and melanoma demonstrated the 
highest levels of PHGDH expression (Figure 1). The 
observed higher expression of PHGDH in breast cancer 
and melanoma cells is in line with previous observations 
regarding elevation of PHGDH in these cell types and 
their potential dependence on PHGDH-mediated supply 
of oncometabolites [4, 5, 14, 15].
Figure 1: PHGDH protein expression levels in different cancer cell lines. PHGDH levels, determined by Western blotting 
and normalised to total protein levels per sample as determined by Ponceau S stain, as well as the PHGDH protein level in K562 cells as 
reference point, were grouped according to their tissue of origin.
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PHGDH-overexpressing MDA-MB-468 are 
susceptible to PHGDH knockdown
Based on our PHGDH protein expression analysis 
together with previous findings reporting PHGDH 
overexpression in a subset of ER- breast cancer cell lines, 
we chose to further assess the effect of PHGDH knockdown 
in three different breast cancer cell lines [4, 7]: two that 
over-express PHGDH (MDA-MB-468, Hs578T) and one 
that expresses relatively little PHGDH (MDA-MB-231). 
siRNA-mediated knockdown by a pool of four sequence-
independent siRNA oligonucleotides resulted in significantly 
reduced PHGDH mRNA and protein levels over at least 120 
hours in all three cell lines (Figure 2A and 2B). Following 
successful knockdown, cell viability was determined in 
colony formation assays. A significant decrease in viability 
was seen in MDA-MB-468 cells, whereas the clonogenic 
potential of Hs578T and MDA-MB-231 cells was not 
affected (Figure 2C). The reduced viability of MDA-
MB-468 cells following PHGDH knockdown supports 
Figure 2: siRNA-mediated knockdown reduces cell proliferation in MDA-MB-468 breast cancer cells. A. PHGDH mRNA 
levels following 72-120 h siRNA-mediated knockdown in three breast cancer cell lines. mRNA expression of PHGDH was normalised to 
GAPDH levels. B. Western blot analysis of PHGDH levels in breast cancer cell lines following PHGDH knockdown. C. Cell proliferation 
measurements determined by colony formation assays. Graph represents averages and standard deviations of three independent experiments 
with three intra-assay repeats. Data is normalised to the respective scrambled siRNA control.
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previous findings from other groups [4, 7], however, no 
effect of PHGDH knockdown was seen in Hs578T cells 
despite similar PHGDH expression in both cell lines.
Differential Scanning Fluorimetry (DSF) 
screening of a fragment library reveals moderate 
affinity binders to PHGDH
In order to identify new PHGDH binders structurally 
different from CBR-5884 and NCT-503 (Figure 3c), a 
fragment-based approach was sought. Compared to high 
throughput screening (HTS), fragment-based drug design 
(FBDD) allows sampling of a relatively large chemical 
space with a comparably low amount of compounds. 
As fragments are of small size and low complexity, the 
likelihood of binding to the target is increased and the 
proportion of atoms involved in target binding is higher 
compared to bigger molecules [16]. Due to the fragments’ 
low molecular weight (< 300 Da), there is still scope to 
develop the fragments into more potent molecules with 
favourable physicochemical properties while staying 
within the margins of size for a drug-like molecule [17].
Figure 3: Screening hits and elaborated hit molecules for PHGDH. A. Structures are presented for the subset of hits identified 
by primary DSF screen that were further evaluated in an ITC competition experiment. B. Modified fragments from the initial screening that 
were subsequently evaluated in an ITC competition experiment. C. Structures of reported PHGDH inhibitors CBR-5884 and NCT-503.
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In this study a ‘rule-of-three’ [18] compliant 
library of 600 fragments (CRT Cambridge, UK) was 
screened against recombinant full-length PHGDH using 
a differential scanning fluorimetry (DSF) assay. PHGDH 
has an average melting temperature (Tm) of 54 °C. 
Fragments were screened at 1 mM in the presence of 1 
% DMSO. 1 mM NADH was used as positive control, 
and gave an increased Tm of 61 °C, corresponding to a 
Δ Tm of 7 °C (Supplementary Figure S2). Hits were 
determined based on an average Z-score ≥ 1, i.e. to a 
change in Tm of PHGDH equal to or greater than one 
standard deviation of the mean (Supplementary Table S5). 
Applying this threshold, 42 compounds were classified as 
hits, which corresponds to a hit rate of 6.4 %. A subset 
of 15 fragments was commercially available and were 
repurchased and further evaluated in an ITC competition 
experiment (Figure 3, Table 1, Supplementary Figure S3). 
The ITC competition experiments confirmed binding of 13 
fragments to the cofactor-binding pocket of PHGDH. Two 
fragments did not affect the binding of NADH to PHGDH 
in this experimental setup, which suggests that these 
fragments are unlikely to bind to the cofactor-binding 
pocket, but does not exclude that they bind at a different 
site on the protein. In order to further characterise the 
hits, and to help us prioritise their use as seeds for further 
hit-expansion studies, we undertook a crystallographic 
investigation of their respective binding modes.
Validation of fragments by X-ray 
crystallography
A crystal structure of the catalytic subunit of 
PHGDH (amino acids (aa) 3-314) with cofactor, NAD+, 
and substrate analogue, L-malate (1), bound to the 
active site has been reported (PDB 2G76). Although 
crystallisation of this catalytic domain of PHGDH 
construct was reproducible in our hands, the crystals 
formed intergrown stacks of sheet-like crystals and 
diffracted to a rather low resolution of 2.7 Å (data not 
shown). In addition, the active site in the crystals was 
partially occupied by the natural cofactor, which co-
purified with the protein and was difficult to remove 
subsequently. In order to identify more suitable protein 
constructs for crystallisation, limited proteolysis was 
performed. This approach has been shown (reviewed in 
14, 15) to be successful in increasing the propensity of 
Table 1: Thermodynamic binding parameters determined by ITC competition.
Fragment ΔH (kJ/mol) ΔS (kJ/ (mol 
x K)
ΔG (kJ/mol) Kd (mM) LE (kJ/(mol x #))
2 No competition
3 -467.2 -1.61 12.8 5.8 ± 2.0 0.23
4 8.3 -0.01 10.8 12.8 ± 2.7 0.21
5 -5.4 -0.07 16.0 1.6 ± 0.2 0.35
6 -1593.9 -5.40 16.1 1.5 ± 0.2 0.38
7 15.8 0.02 10.2 16.6 ± 10.4 0.15
8 -292.7 -1.02 12.7 5.9 ± 1.5 0.28
9 -102.0 -0.38 11.2 11.1 ± 5.0 0.24
10 -260.8 -0.91 11.6 9.3 ± 3.8 0.23
11 -11.5 -0.08 11.1 11.5 ± 8.4 0.18
12 -64.4 -0.25 11.0 11.8 ± 9.6 0.22
13 No competition
14 -47.0 -0.19 9.0 26.2 ± 31.8 0.20
15 -1753.2 -5.93 14.5 2.8 ± 1.6 0.27
16 -382.6 -1.33 12.5 6.5 ± 4.7 0.30
17 -1517.3 -5.14 14.9 2.4 ± 0.7 0.32
18 -194.3 -0.67 10.3 15.9 ± 7.4 0.22
19 -190.1 -0.67 10.3 15.4 ± 10.2 0.22
20 Compound precipitated
Changes in entropy (ΔS) and enthalpy (ΔH) as well as the binding constant (KD) were determined. LE was calculated as the 
coefficient of ΔG per number of non-hydrogen atoms (= #).
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proteins to crystallise because proteases primarily cut at 
solvent accessible and flexible or unstructured sites, thereby 
reducing the target to relatively stable protein cores [19, 20].
Proteolysis was performed by mixing 
PHGDH with five different proteases separately 
(papain, endoproteinaseGlu-C, thermolysin, trypsin and 
chymotrypsin) in 1:100 and 1:1000 molar ratios. The 
mixtures were incubated at room temperature (RT) 
or 37 °C for one hour and analysed by SDS-PAGE 
(Figure 4). Cleanest cleavage was seen with thermolysin 
at 37 °C which resulted in cleavage of PHGDH into two 
fragments, one of 36 kDa, which is likely to correspond 
Figure 4: Limited proteolysis and domain composition of PHGDH. A. 100 µg or 50 µg PHGDH or sPHGDH was mixed 
with five different proteases at molar ratios of 1:100 and 1:1000. The digestion was performed for 1 h at RT or 37 °C and analysed by 
SDS-PAGE. B. A comparison of the structural elements comprising human PHGDH, sPHGDH and PHGDH-93. Amino acids involved in 
hydrogen bond formation to the substrate (*) or cofactor NAD+ (*) are highlighted. C. A comparison of the 3D structures of sPHGDH and 
PHGDH-93. (i) A ribbon diagram of PHGDH-93 (coloured model) is shown superimposed on sPHGDH (grey). (ii) Ribbon diagram of 
PHGDH-93 with bound cofactor NAD+.
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to the shorter PHGDH fragment (aa 3-314) already used 
for crystallisation, and a smaller fragment of 26 kDa 
(Figure 4, lane 7).
Subjection of the 26 kDa cleavage product to ESI-
MS, combined with knowledge of the preferred cleavage 
sites of thermolysin, allowed us to narrow down the 
potential amino acid sequences of the proteolytically-
derived PHGDH fragments (Supplementary Figure S4). 
According to this analysis, the most abundant product 
of proteolysis corresponded to amino acids 93-298. 
Accordingly, we prepared a His-tagged E. coli expression 
construct for a truncated protein corresponding to 
this fragment (termed PHGDH-93), which could be 
recombinantly expressed and purified by affinity and 
gel filtration chromatography. The measured OD260/280 
ratio of 0.71 for purified PHGDH-93 indicated a degree 
of contamination with co-purifying cofactor (NAD+ and/
or NADH), and therefore the protein was subjected to 
charcoal treatment prior to crystallisation. PHGDH-93 was 
then successfully crystallised with an empty, accessible 
cofactor-binding pocket. Comparison with the available 
PHGDH structure (2G76) showed that PHGDH-93 was 
missing a lid domain, which partly encloses the substrate-
binding site. As PHGDH-93 does not contain this lid 
domain necessary for substrate binding, the protein 
construct lacks catalytic activity compared to sPHGDH 
(data not shown). However, the core domain of PHGDH, 
which includes the cofactor-binding site, was properly 
folded in PHGDH-93 and overlaid well onto the published 
structure as well as giving stable crystals (Figure 4c). Thus 
PHGDH-93 provides a valuable tool to investigate binders 
to the cofactor-binding site.
Soaking of all 15 fragments into PHGDH-93 
crystals was performed overnight at RT using a fragment 
concentration of 80 mM in 20 % DMSO. X-ray diffraction 
data were collected from the soaked crystals at the 
DIAMOND Light Source (DLS) to resolutions of between 
1.3 and 1.7 Å (Supplementary Table S6). Difference 
electron density corresponding to seven fragments (3, 5, 9, 
10, 14-16, 47 % of tested compounds) was clearly visible. 
All of the fragments for which crystallographic data 
were obtained bound to the adenine-pocket suggesting 
this pocket to be a preferential site for fragment binding 
(Figures 5 and 6). Analysis of the fragments’ binding 
modes showed that four of the fragments (5, 14, 15 and 
16) were coordinated by hydrogen and/or halogen bonds 
(Figure 5), whereas the other three fragments (3, 9 and 
10) appeared to be stabilised only by apolar contacts 
(Figure 6). Of the four compounds forming specific 
interactions with the protein, fragments 5 (3-chloro-4-
fluorobenzamide), 14 (5-fluoro-2-methylbenzoic acid) and 
15 (N-(3-chloro-4-methoxyphenyl)acetamide) constitute 
substituted benzene rings. The most potent compound 
according to the ITC data, fragment 5, bound more deeply 
in the adenine binding pocket compared to the other two 
structurally similar fragments, and formed an halogen bond 
with the backbone carbonyl of Gly151 through its chloro 
atom and a hydrogen bond with the side-chain of Ser211 
(Figure 5A and 5B). Fragment 15 formed a similar halogen 
bond interaction with Gly151 through a chloro-substituent 
(Figure 5E and 5F). Fragment 14 was substantially less 
potent (Kd = 26 ± 31 mM) compared to the two structurally 
similar fragments 5 and 15 (5, Kd = 1.6 ± 0.2 mM and 15, 
Kd = 2.8 ± 1.6 mM). However, fragment 14 still formed a 
hydrogen bond with the side-chain of Asp174 and a water 
molecule present in the binding pocket (Figure 5C and 
5D). Fragment 16 (3-hydroxybenzisoxazole) made one 
hydrogen bond with the side-chain of Ser211 through its 
hydroxyl functional group (Kd = 6.5 ± 5.7 mM) (Figure 
5G and 5H). Despite a similar bicyclic structure, fragment 
9 (5-amino-1-methyl-1H-indole, Kd = 11.1 ± 5.0 mM) 
bound to the adenine pocket in a 180 °-flipped orientation 
compared to the 3-hydroxybenzisoxazole (16) (Figure 
6C and 6D). Thus, the N1-methylated fragment 9 pointed 
into a small hydrophobic pocket. The remaining two 
crystallographically observed fragments, 3 (1-methyl-3-
phenyl-1H-pyrazol-5-amine) and 10 (3-(1,3-oxazol-5-yl)
aniline) were non-fused bicyclic aromatic systems, which, 
although not forming specific hydrogen bonds to the 
protein, bound in a similar orientation to one another to 
the adenine pocket (3, Kd = 5.8 ± 2.0 mM and 10, Kd = 9.3 
± 3.8 mM) (Figure 6A, 6B, 6E and F).
Fragment growth allows further exploration of 
the binding pocket
Based on the fragment crystal structures, fragment 
16 was selected for modification to further explore the 
binding site and potential vectors for fragment growth.
The binding mode of fragment 16 revealed two 
potential routes for fragment growth: (1) growth out of 
the cofactor-binding pocket from C-4 or C-5 and (2) 
fragment growth from the 3-hydroxy position along the 
cofactor-binding pocket from the adenine site towards the 
nicotinamide-binding site. In addition a small hydrophobic 
pocket adjacent to the fragment was detected that could be 
filled with a small hydrophobic group by substitution at 
position C-6 or C-7 of the benzisoxazole so as to increase 
interactions with the protein. To investigate this small 
pocket, the 6-chloro (17) and 7-methyl (18) substituted 
3-hydroxybenzisoxazoles were investigated. Addition 
of the chloro-substituent improved fragment binding to 
sPHGDH as shown by competitive ITC (16, Kd = 5.8 ± 
4.7 mM and 17, Kd = 2.4 ± 0.7 mM), whereas the 7-methyl 
analogue showed 2.5-fold reduced affinity (18, Kd = 15.9 
± 7.4 mM) (Table 1). Crystal structures of these fragments 
in complex with PHGDH-93 showed that the 7-methyl 
analogue (18) adopted an orientation flipped by 180° 
along a horizontal axis compared to fragment 16. In this 
orientation, the 7-methyl group pointed towards a route 
for fragment growth out of the pocket (Figure 7C). In 
addition, the previously formed hydrogen bond between 
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Figure 5: X-ray crystal structures of fragments forming specific hydrogen and/or halogen bonds with PHGDH. Crystal 
structures of bound fragment 5 (A. and B., 1.53 Å resolution), 14 (C. and D., 1.53 Å resolution), 15 (E. and F., 1.53 Å resolution) and 16 
(G. and H., 1.33 Å resolution) are shown. The Fo-Fc omit electron density maps are shown as green wire at contour levels of 0.5 electrons/
Å3. The left-hand panels show the protein as a grey ribbon representation with selected side-chains drawn as sticks with carbon atoms in 
grey. The right-hand panels show the protein surface coloured by electrostatic potential.
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Figure 6: X-ray crystal structures of fragments not showing specific interactions bound to the adenine-subsite of 
PHGDH. Crystal structures of bound fragment 3 (A. and B., 1.33 Å resolution), 9 (C. and D., 1.53 Å resolution) and 10 (E. and F., 1.53 
Å resolution) are shown. The Fo-Fc omit electron density map is shown as green wire at contour levels of 0.5 electrons/Å
3. The left-hand 
panels show the protein as a grey ribbon representation with selected side-chains drawn as sticks with carbon atoms in grey. The right-hand 
panels show the protein surface coloured by electrostatic potential.
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Ser211 and the 3-hydroxy group of fragment 16 (Figure 
7A) was no longer formed, but instead the oxygen group 
within the isoxazole moiety of fragment 18 was brought 
into close proximity of Ser211 for potential hydrogen bond 
formation. Fragment 17 adopted the same orientation as 
fragment 18, forming the previously described hydrogen 
bond between O-1 and Ser211. In this position the 
5-chloro-substituent occupied a small hydrophobic pocket 
(Figure 7D). This additional interaction with the protein is 
likely to lead to the observed increase in binding affinity 
of fragment 17 compared to 16 and 18.
The preference of this pocket for small hydrophobic 
groups was also seen with 3-hydroxybenzisoxazoles 
carrying halogen substituents at the C-5 position. For 
example, the crystal structure of PHGDH-93 with 5-fluoro-
3-hydroxybenzisoxazole (19) showed that the fluoro-group 
occupied also the hydrophobic pocket whilst adopting a 
similar orientation as the 6-chloro analogue (17) (Figure 
8B). However, with the fluoro-substituent being in the 
5-position, fragment 19 adopted a position which allowed 
for hydrogen bond formation not only with Ser211, but 
additionally through its 3-hydroxy moiety with Asp174 
(Figure 8D). Interestingly, despite the additional hydrogen 
bond and the occupation of the small hydrophobic pocket, 
the binding affinity of fragment 19 was 6-fold weaker 
compared to the 6-chloro-3-hydroxybenzisoxazole (17) 
(19, Kd = 15.4 ± 10.2 mM). For the 5-bromo analogue 
(20) the hydrophobic pocket was too small to fully 
accommodate the bromide substituent, and the fragment 
core was shifted with respect to the position observed 
for 16 (Figure 8A and 8C). In this position, fragment 20 
was able to maintain the hydrogen bond formation with 
Ser211, but no further interactions with the protein were 
observed and, due to compound precipitation, no binding 
affinity was detected.
DISCUSSION
PHGDH has recently been shown to be a potential 
therapeutic target in cancer types that overexpress 
PHGDH [4, 5]. In our study we confirmed that knockdown 
of PHGDH resulted in significant growth reduction in the 
PHGDH-amplified breast cancer cell line MDA-MB-468 
[4]. In contrast to previous observations, however, we 
found that Hs578T, a breast cancer cell line with relatively 
high PHGDH protein expression levels, but without a 
Figure 7: Binding of 3-hydroxybenzisoxazole and analogues with substituents at positions 5 and 7. Binding of fragments 
16 (cyan), 17 (yellow) and 18 (green) to the adenine-binding pocket of PHGDH-93. A. Fragment 16, B. fragments 16, 17 and 18, C. 
fragments 16 and 18, D. fragments 16 and 17. The protein is shown in ribbon representation in grey together with the protein surface 
coloured by electrostatic potential. The compound surfaces are coloured to match the carbon atoms of the respective fragment. Hydrogen 
bonds are shown as dashed lines. Blue arrows in pictures (C) and (D) highlight the position of the introduced substituents compared to 
parent fragment 16.
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genomic amplification of PHGDH, was insensitive to 
PHGDH knockdown, as was the non-amplified and low-
expressing MDA-MB-231 [4]. The growth inhibition 
effect seen in PHGDH-amplified breast cancer cells, 
together with increasing evidence of the prevalence of 
PHGDH expression in certain cancer types, makes the 
design of a PHGDH inhibitor highly desirable to allow for 
further target validation using a chemical probe.
In our approach, we started from a fragment 
screen of a library of 600 fragments using DSF [21-23]. 
To validate the hits from this screen, we implemented a 
competition-based isothermal titration calorimetry assay. 
This assay allows measurement of the fragment’s binding 
affinity, broken down into separate thermodynamic 
contributions. Moreover, it tests the fragment’s ability 
to interfere with co-factor binding, where the DSF 
screen tests only the ability to bind to PHGDH. Thus, 
the competition ITC assay provided a relatively 
information-rich modality for hit validation, although at 
relatively low throughput. The 15 fragment hits selected 
from the DSF output showed a range of binding affinities 
in the competitive ITC experiment, confirming a non-flat 
SAR in ligand binding to PHGDH and providing cause for 
optimism for further inhibitor development.
To determine the fragment’s binding modes by 
X-ray crystallography, a new PHGDH construct was 
sought which was more stable and thus would more 
readily crystallise. Limited proteolysis with thermolysin 
revealed a stable fragment of PHGDH consisting of the 
core of the catalytic domain containing the cofactor-
binding site, and this was shown to crystallise readily. The 
resultant crystals diffracted to high resolution. Comparison 
of crystal structures of the enzymatically active fragment 
sPHGDH and the shorter construct 93, showed that the 
cofactor-binding site was formed identically in both 
constructs. Using this construct, fragment hits identified 
by DSF and confirmed by competition ITC were soaked 
into PHGDH crystals. Around half of the fragments 
validated by ITC were shown to bind to PHGDH by X-ray 
crystallography, and all of these bound to the adenine-
subsite. The fragment screen allowed the identification of 
a diverse set of new scaffolds with relatively similar Kd 
Figure 8: Binding mode of 5-fluoro/bromo-3-hydroxybenzisoxazole to the adenine-binding subsite. Binding of fragments 
16 (cyan), 19 (magenta) and 20 (coral) to the adenine-binding pocket of PHGDH-93. A. Fragment 16, B. fragments 16 and 19, C. fragments 
16 and 20, D. fragment 16 and 19. The protein is shown in ribbon representation in grey together with the protein surface coloured by 
electrostatic potential. The compound surfaces are coloured according to match the carbon atoms of the respective fragment. (D) Hydrogen 
bonds between fragment 16 or 19 and PHGDH-93 are shown as dashed lines.
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in the low mM-range. These fragments provide several 
avenues for further elaboration into larger fragments to 
increase potency and establish SARs. Through growth 
of fragment 16, the binding mode of some of the new 
modified fragments compared to the parental fragment had 
changed. This is likely to be due to the fact that fragment 
16 initially only formed a specific interaction with one side 
chain (Ser211) of the protein and thus, through growth of 
the parental fragment, e.g. further addition of functional 
groups, the position of the new fragments can shift in order 
to be able to increase the number of specific interactions 
with the protein. In addition, the initial fragment hits are 
small compared to the adenine-binding site, which allows 
the fragments to adjust their position within the pocket.
Here, we show for the first time a fragment-based 
approach for the design of PHGDH binders, for which to 
date only two small molecule inhibitors, CBR-5884 [13] 
and NCT-503 [12], have been reported. The compounds 
identified and characterised in this work are structurally 
different from the reported PHGDH inhibitors CBR-5884 
[13] and NCT-503 [12] (Figure 3c), and thus provide a 
new starting point for the design of potent and selective 
PHGDH inhibitors. CBR-5884 is a non-competitive 
inhibitor that prevents the oligomerisation of PHGDH, 
whereas NCT-503, also a non-competitive inhibitor 
in regards to substrate and cofactor, is supposed to 
bind close to the active site as mutation of C234 in the 
active site of the protein reduces the inhibitory effect of 
PHGDH. The presented hit fragments in this study bind 
competitively to NAD at the cofactor-binding site of 
PHGDH, and therefore serve as starting points for an 
orthogonal approach to PHGDH inhibition. Development 
of a competitive inhibitor will be valuable to investigate 
the effects of reversible PHGDH inhibition. In addition, 
studies on kinases, which represent a well-studied class 
of cancer targets, have shown that while drug-resistant 
mutants of protein kinases have emerged for both 
allosteric and competitive compounds, to date no resistant 
mutations have been reported where an allosteric and an 
ATP-competitive inhibitors of a given kinase have been 
used in combination [24, 25]. As such, it appears sensible 
to pursue the development of both allosteric and cofactor 
competitive inhibitors for oncology targets.
MATERIALS AND METHODS
Cell culture
Breast cancer cell lines MDA-MB-231, MDA-
MB-468 and Hs578T were obtained from the American 
Type Culture Collection (Manassas, VA, USA). All cell 
lines were cultured in RPMI 1640 supplemented with 10 
% FBS, penicillin (100 U/mL) and streptomycin (1.0 mg/
mL) (Sigma Aldrich, St Louis, MO, USA). Lysates of 
other cell lines analysed for their PHGDH protein levels 
were obtained from research groups within the Northern 
Institute for Cancer Research (Newcastle University, UK).
Transient siRNA knockdown
Transient knockdown of PHGDH was achieved 
in cells using a pool of four individual siRNAs 
(siPHGDH01 GGAAAUUGCUGUUCAGUUC, siPHG 
DH02 CGACAGGCUUGCUGAAUGA, siPHGDH03 
GACCCUUGCUGCCGGAAAGA and siPHGDH04 
UGAACUUGGUGAACGCUAA) at 5 nM (ON-TARGET 
plus, Dharmacon). For the non-target control, a pool 
of four individual siRNAs was used (UGGUUU 
ACAUGUCGACUAA, UGGUUUACAUGUUGUGUGA, 
UGGUUUACAUGUUUUCUGA, 
UGGUUUACAUGUUUUCCUA).
Quantitative real-time PCR (qRT-PCR)
Total RNA was isolated using Trizol. qRT-PCR 
was performed in triplicate using specific primers for 
PHGDH (forward primer CACGACAGGCTTGCT 
GAATGA, reverse primer CTTCCGTAAACACGTCC 
AGTG) and GAPDH (forward primer CGACCACTTT 
GTCAAGCTCA, reverse primer GGGTCTTACT 
CCTTGGAGGC). qRT-PCR was performed with 0.5-0.75 
μg cDNA in a final volume of 10 μL. The reactions were 
run in the presence of Platinum® SYBR® Green qPCR 
SuperMix-UDG (Thermo Fisher Scientific) and analysed 
through correction for GAPDH transcription level.
Western blotting
Cells were lysed in PhosphoSafe™ extraction 
reagent (EMD Millipore), followed by sonication. Cell 
lysates (10 μg total protein/lane loaded) were separated 
by SDS-PAGE and transferred onto nitrocellulose 
membrane. Total protein content was visualised by 
PonceauS staining (0.1 % (wt/vol) Ponceau S in 5 % 
(vol/vol) acetic acid), quantified and used as loading 
control. Membranes were blocked in 5 % (wt/vol) milk 
in Tris buffered saline with 0.1 % Tween20 (TBS-T) 
for one hour at RT followed by incubation overnight 
at 4 °C with primary antibody (anti-PHGDH; Sigma 
Aldrich HPA021241 and anti-GAPDH; SantaCruz 
biotechnology Sc-25778) diluted 1:1000 in 5 % (wt/
vol) milk in TBS-T. The membranes were then washed 
twice in TBS-T and incubated with HRP-conjugated 
secondary antibody diluted 1:2000 in 5 % (wt/vol) milk 
in TBS-T for one hour at RT. After several washes, 
proteins were detected by chemiluminescence using 
Amersham ECL Western blotting detection reagent 
(GE Healthcare) according to the manufacturer’s 
instructions. K562 cell lysate was used as a quality 
control against which all samples were compared.
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Colony formation assay
Following a 48 hour treatment with siRNA as 
described (see section transient siRNA knockdown), cells 
were reseeded at specific densities in complete medium. 
Cells were left to form colonies (> 30 cells) for up to 16 
days, depending on the proliferation rate of the individual 
cell line. After fixation of cells with Carnoy’s fixative 
(methanol: acetic acid, 3:1, vol/vol), colonies were stained 
with 1 % crystal violet solution in 10 % aqueous ethanol. 
Colonies were counted by eye and cloning efficiency 
calculated.
Cloning
The pNIC28-Bsa4 plasmids containing the human 
PHGDH cDNA encoding for the full-length enzyme (aa 
1-533) as well as the truncated version (sPHGDH, aa 
3-314) were kindly donated by Wyatt Yue (SGC Oxford). 
Both plasmids were fused with an N-terminal His6-tag and 
a Tobacco Etch Virus (TEV) protease recognition site.
Protein expression and purification
PHGDH, sPHGDH and PHGDH-93 were 
expressed in E. coli Rosetta (DE3) grown at 37 °C in 
Terrific Broth (TB). Protein expression was induced with 
0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) 
and the cells grown for a further 18 hours at 20 °C. Cell 
pellets were resuspended in extraction buffer (50 mM 
NaH2PO4, pH 8, 10 mM imidazole, 300 mM NaCl, 0.5 
mM TCEP) supplemented with 0.05 mg/mL RNase A, 
0.01 mg/mL Dnase, 0.25 mg/mL lysozyme, 5 mM MgCl2 
and EDTA-free Complete™ protease inhibitors (Roche). 
Cells were lysed by sonication and then clarified by 
centrifugation (60,000 x g, 1 hour). PHGDH and shorter 
variants thereof were subsequently purified by affinity 
chromatography (HisTrap Ni-Sepharose column, GE 
Healthcare) followed by cleavage of the His6-tag with 
TEV protease (1:25 wt/wt at 4 °C overnight). Further 
purification of the proteins was achieved by size-
exclusion chromatography (Superdex 75 26/60 (GE 
Healthcare)) in size exclusion buffer (25 mM HEPES, 
pH 7.5, 100 mM NaCl, 0.5 mM TCEP).
Differential scanning fluorimetry
The DSF assay was performed in 384-well plates 
(Corning, black) in 25 mM HEPES, pH 7.5, 100 mM 
NaCl, 0.5 mM TCEP, 10 x SYPRO® Orange (Thermo 
Fisher Scientific), in a final volume of 15 μL containing 
15 μM PHGDH and 2 % (vol/vol) DMSO. The fragments 
were added from a 100 mM master stock in 100 % DMSO 
to a final concentration of 1 mM using an ECHO® 
acoustic liquid handler (Labcyte). Reference wells 
contained DMSO only and 1 mM NADH was used as 
positive control.
The heat denaturation profile of PHGDH was 
followed using the fluorescence of Sypro Orange with 
excitation and emission wavelengths of 470 and 570 nm, 
respectively. Analysis was performed in GraphPad Prism 
using the Boltzmann equation to determine the melting 
temperature, Tm, which is the inflection point of the 
sigmoidal denaturation curve.
ITC competition experiments
ITC experiments were performed in 25 mM 
HEPES, pH 7.5, 100 mM NaCl, 0.5 mM TCEP in a 
MicroCal iTC200 instrument (GE Healthcare). To remove 
residual bound cofactor, sPHGDH was incubated with 0.5 
equivalents of activated charcoal for 30 minutes at room 
temperature prior to performing the ITC experiments. 
For the competition ITC, 0.5 mM NADH mixed with 
the fragment of interest at 5 mM final concentration in 
5 % (v/v) DMSO was titrated into 0.05 mM sPHGDH 
also premixed with 5 mM fragment at 25 °C. 1 x 0.5 μL, 
followed by 17 x 2 μL injections of ligands into protein 
with 120 seconds spacing between the injections was 
conducted. Titration of 0.5 mM NADH in 5 % DMSO into 
0.05 mM sPHGDH in 5 % DMSO was used as reference. 
The thermodynamic parameters of the reactions were 
determined using ORIGIN version 7.0 (OriginLab), and 
the thermodynamic parameters for the fragments were 
derived as described [26].
Limited proteolysis
100 μg sPHGDH or PHGDH were mixed with 
different proteases (papain, endoproteinase Glu-C, 
thermolysin, trypsin, chymotrypsin) at a molar ratio of 
1:100 and 1:1000. Proteolysis was performed for one 
hour at RT or 37 °C prior to separation of the reaction 
mixture by SDS-PAGE. Characterisation of stable protein 
fragments was performed by liquid chromatography-mass 
spectrometry (LC-MS) using the liquid protein-protease 
mixture (Mass Spectrometry Facility, University of 
Leeds).
X-ray crystallography
Crystals of PHGDH-93 were grown in 0.1 M PCTP 
buffer, pH 7 with 23-28 % (w/v) PEG 1500 at 20 °C by 
sitting drop vapour diffusion. Plates were set up using a 
Mosquito LCP liquid handler (TTP Labtech, Melbourn, 
UK) with two drops of 300 nL protein (15 mg/mL) mixed 
with 300 or 600 nL precipitant and a shared reservoir 
solution of 70 μL. Fragments were soaked into PHGDH-93 
crystals at a concentration of 80 mM overnight in soaking 
buffer, which was a mixture of the reservoir buffer (25 % 
PEG 1500, 0.1 M PCTB pH 7) and the gel filtration buffer 
used for the protein purification (25 mM HEPES, pH 7, 
100 mM NaCl, 0.5 mM TCEP) at a 3:2 ratio supplemented 
with 20 % (v/v) DMSO. Crystals were cryo-protected in 
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soaking buffer supplemented with 15 % (wt/vol) PEG400 
before being flash cooled in liquid nitrogen. Diffraction 
data were collected at the Diamond Light Source (DLS) on 
beamlines I02, I03, I04 and I04-1 (Supplementary Table 
S6). Data were processed and the structure solved using 
xia2 [27] and programs from the CCP4 suite [28] and the 
deposited structure of human PHGDH (PDB 2G76) as a 
starting model for molecular replacement. The structures 
were refined with iterative cycles of manual correction in 
COOT [29] followed by refinement with Refmac5 [30] 
within CCP4i2 [28]. Supplementary Table S6 summarises 
the X-ray crystallographic data collection and refinement 
statistics. As is often the case for low affinity ligands, the 
electron density suggested that multiple bound poses were 
present for some of the fragments for which structures 
were determined. The discussion and figures represent 
what appeared to be that pose with the highest occupancy.
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